Fergusson R J, Fisken J, McIntyre M A, Roulston J E, Leonard R C
Department of Clinical Oncology, Western General Hospital, Edinburgh.
J Clin Pathol. 1992 Dec;45(12):1114-5. doi: 10.1136/jcp.45.12.1114.
The usefulness of placental alkaline phosphatase (PLAP) as a diagnostic marker of malignancy was assessed in pleural fluid from 60 patients with effusions. Pleural fluid PLAP activities were measured by an enzyme linked immunoassay (ELISA) using the two monoclonal antibodies H17E2 and H317. Similar values were found in groups of patients with primary bronchial tumours (n = 12), secondary malignancies (n = 23), and "benign" conditions (n = 25). The highest values were found in a small subgroup of patients with metastatic ovarian carcinoma. However, the production of this enzyme by normal lung makes the measurement of PLAP in pleural fluid unhelpful as a diagnostic aid to distinguish "benign" from malignant effusions.
对60例胸腔积液患者的胸水进行检测,评估胎盘碱性磷酸酶(PLAP)作为恶性肿瘤诊断标志物的效用。使用两种单克隆抗体H17E2和H317,通过酶联免疫吸附测定法(ELISA)测量胸水PLAP活性。在原发性支气管肿瘤患者组(n = 12)、继发性恶性肿瘤患者组(n = 23)和“良性”疾病患者组(n = 25)中发现了相似的值。在一小部分转移性卵巢癌患者中发现了最高值。然而,正常肺组织会产生这种酶,这使得胸水PLAP的测量无助于区分“良性”和恶性胸腔积液,不能作为诊断辅助手段。